LOGIN  |  REGISTER
Chimerix
Recursion

Neogen to Participate in the 36th Annual Piper Sandler Healthcare Conference

November 27, 2024 | Last Trade: US$5.21 0.30 6.11

LANSING, Mich., Nov. 27, 2024 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today that the Company will participate in the 36th Annual Piper Sandler Healthcare Conference in New York City on Wednesday, December 4, 2024.

John Adent, Neogen's President and Chief Executive Officer, will present at 11:00 a.m. Eastern Time.

To access the webcast and presentation materials, please visit the Events & Presentations section of the Neogen Investor Relations website at neogen.com/investor-relations/events-presentations and click on the event webcast link.

About Neogen

Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.

Media Contact

Bill Waelke, Vice President, IR & Treasury
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Recursion

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page